2. Search Result
Search Result
Results for "

CK2-IN-1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145260
    BRD4/CK2-IN-1

    		Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy Cancer
    BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)
    BRD4/CK2-IN-1
  • HY-148318
    CK2α-IN-1

    		Casein Kinase Cancer
    CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies .
    CK2α-IN-1
  • HY-156816
    ON 108600

    		Casein Kinase DYRK Cancer
    ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC50s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .
    ON 108600
  • HY-15260
    XL413
    4 Publications Verification

    BMS-863233

    		 CDK Cancer
    XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413
  • HY-15260A
    XL413 monohydrochloride
    4 Publications Verification

    BMS-863233 monohydrochloride

    		 CDK Cancer
    XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413 monohydrochloride
  • HY-149006
    CK156

    		DAPK Inflammation/Immunology Cancer
    CK156 is a highly selective death-associated protein kinase (DAPK) inhibitor with IC50s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases .
    CK156
  • HY-121792
    CK2-IN-1

    		Casein Kinase Others
    CK2-IN-1 is a CK2 inhibitor, with an IC50 of 150 nM .
    CK2-IN-1
  • HY-158371
    HDAC/CK2-IN-1

    		HDAC Casein Kinase Cancer
    HDAC/CK2-IN-1 (compound 38) is a HDAC1 (IC50 = 1.46 μM), HDAC6 (IC50 = 0.66 μM), and CK2 (IC50 = 3.67 μM) inhibitor. HDAC/CK2-IN-1 exhibits promising antproliferative activity against Jurkat, MCF-7, HCT-116, and HL-60 cell lines .
    HDAC/CK2-IN-1
  • HY-135816
    CK2/PIM1-IN-1

    		Casein Kinase Pim Inflammation/Immunology Cancer
    CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .
    CK2/PIM1-IN-1
  • HY-117332
    IQA

    CGP-029482

    		 Casein Kinase Cancer
    IQA (CGP-029482) is a potent and selective protein kinase CK2 inhibitor .
    IQA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: